Interleukin-23 inhibitors

---

Adisen E.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, ss.61-66, 2022 (ESCI, Scopus, TRDizin)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 56
• Basım Tarihi: 2022
• Doi Numarası: 10.4274/turkderm.galenos.2022.06337
• Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.61-66
• Anahtar Kelimeler: IL-23 inhibitor, guselkumab, tildrakizumab, risankizumab, PHASE-III, VOYAGE 1, PLAQUE PSORIASIS, GUSELKUMAB, EFFICACY, TILDRAKIZUMAB, MODERATE, SAFETY, ANTIBODY, TRIAL
• Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
• Gazi Üniversitesi Adresli: Evet

Özet

For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis patients being treated with IL-23 inhibitors. In patients with partial response, dose increase may be planned, or topical corticosteroids, vitamin D analogs, methotrexate, or phototherapy (UVB) may be added to the treatment.